Title: The View Beyond Single-Agent Blockade: Combination strategies in Lung
Cancer
Michel van den Heuvel, Netherlands Cancer Institute / Antoni van Leeuwenhoek,
Amsterdam
Abstract: With the arrival of active immunoncology drugs (IOD) is has finally
been achieved to improve survival for patients with metastasized lung cancer.
The response rate to PD(L)1 antibodies is 20-30% and this response is durable.
The majority however, still does not benefit and therefore other strategies need
to be developed. This has now become feasible by combining IOD with other
knows anti-cancer treatment. No definitive prove is available as to date but the
large phase one trials and phase 2 trials have shown that combining PD(L)1
antibodies and CTLA4 antibodies or chemotherapy is feasible and first efficacy
results are promising. Phase 3 trials are ongoing for the combination of
nivolumab with ipilimumab, of durvalumab with tremilimumab, and of PD(L)1
antibodies with chemotherapy. Another strategy to improve survival is to move
treatment to earlier stages of disease by combining it with surgery or
chemoradiotherapy. During the presentation the early data on the combination
strategies will be reviewed.